1. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910. Yale J Biol Med 2001;74:179–84.
2. Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Front Physiol 2020;11:435.
3. Lehmann H, Cutbush M. Sub-division of some Southern Indian communities according to the incidence of sickle-cell trait and blood groups. Trans R Soc Trop Med Hyg 1952;46:380–3.
5. Mangla A, Ehsan M, Agarwal N, Maruvada S. Sickle cell anemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024.
6. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol 2019;14:263–92.
10. Cox SE, Hart E, Kirkham FJ, Stotesbury H. L-Glutamine in sickle cell disease. Drugs Today (Barc) 2020;56:257–68.
11. Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med 2018;379:226–35.
12. Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2017;376:429–39.
13. Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med 2019;381:509–19.
19. Lehrer-Graiwer J, Yokoshima L, Tong B, Love TW. Accelerated approval of Oxbryta® (voxelotor): a case study on novel endpoint selection in sickle cell disease. Contemp Clin Trials 2020;98:106161.
21. Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, et al. Discovery of GBT440, an orally bioavailable R-state stabilizer of sickle cell hemoglobin. ACS Med Chem Lett 2017;8:321–6.
22. Torres L, Conran N. Emerging pharmacotherapeutic approaches for the management of sickle cell disease. Expert Opin Pharmacother 2019;20:173–86.
24. Patel M, Oksenberg D, Silva A, Betz A, Metcalf B, Sinha U. GTx011, a novel agent that improves rheological properties of sickle cell blood by increasing oxygen affinity for hemoglobin. Blood 2013;122:2207.
25. Patel M, Cabrales P, Dufu K, Metcalf B, Sinha U. GTx011, an anti-sickling compound, improves SS blood rheology by reduction of HbS polymerization via allosteric modulation of O
2 affinity. Blood 2014;124:1370.
26. Patel MP, Siu V, Silva-Garcia A, Xu Q, Li Z, Oksenberg D. Development and validation of an oxygen dissociation assay, a screening platform for discovering, and characterizing hemoglobinoxygen affinity modifiers. Drug Des Devel Ther 2018;12:1599–607.
28. Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 2021;8:e323–33.
29. Blyden G, Bridges KR, Bronte L. Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access. Am J Hematol 2018;May 12 doi:
10.1002/ajh.25139. [Epub].
32. Shah N, Lipato T, Alvarez O, Delea T, Lonshteyn A, Weycker D, et al. Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis. Expert Rev Hematol 2022;15:167–73.
36. Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769–78.
37. Wang WC, Kovnar EH, Tonkin IL, Mulhern RK, Langston JW, Day SW, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 1991;118:377–82.
38. Voeks JH, Gray S, Lehrer-Graiwer J, Adams RJ. Correlation between hemoglobin levels and transcranial doppler velocities: a retrospective STOP 2 analysis in children with sickle cell disease. HemaSphere 2020;4(S1): 710–11.
39. Phan V, Hershenson J, Caldarera L, Larkin SK, Wheeler K, Cortez AL, et al. Effect of voxelotor on cardiopulmonary testing in youths with sickle cell anemia in a pilot study. Pediatr Blood Cancer 2023;70:e30423.
40. The effect of voxelotor on cerebral hemodynamic response in children with sickle cell Anemia (VoxSCAN) study [Internet]. Bethesda (MD): ClinicalTrials.gov; 2024 [cited 2024 Jun 10]. Available from:
https://clinicaltrials.gov/study/NCT05018728.
41. An open-label extension study of voxelotor administered orally to participants with sickle cell disease who have participated in voxelotor clinical trials [Internet]. Bethesda (MD): ClinicalTrials.gov; 2024 [cited 2024 Jun 10]. Available from:
https://clinicaltrials.gov/study/NCT04188509.
42. Study to assess the effect of long-term treatment with voxelotor in participants who have completed treatment in study GBT440-031 (034OLE) [Internet]. Bethesda (MD): ClinicalTrials.gov; 2024 [cited 2024 Jun 10]. Available from:
https://clinicaltrials.gov/study/NCT03573882.
43. A phase 3, randomized, double-blind, placebo-controlled study of voxelotor (GBT440) in pediatric participants with sickle cell disease (HOPE Kids 2) [Internet]. Bethesda (MD): ClinicalTrials.gov; 2024 [cited 2024 Jun 10]. Available from:
https://clinicaltrials.gov/study/NCT04218084.
44. Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options [Internet]. Bethesda (MD): Clinical Trials.gov; 2024 [cited 2024 Jun 10]. Available from:
https://clinicaltrials.gov/study/NCT04724421.